Feasibility and Acceptability of Cognitive Behavioral Therapy for Chronic Insomnia in a Primary Care

Sponsor
Balearic Islands Health Service (Ibsalut) (Other)
Overall Status
Completed
CT.gov ID
NCT04565223
Collaborator
(none)
32
2
14

Study Details

Study Description

Brief Summary

This pilot-feasibility study of a cluster parallel randomized design comparing CBT-i against usual care (UC) was performed at two primary health care centers in Majorca, Spain. Patients were included if they were 18 to 65 years-old; had diagnoses of chronic insomnia according to the Insomnia Severity Index (ISI more than 8) and had insomnia longer than 3 months; and did or did not use a hypnotic medication. 25 GPs and nurses and 32 patients were randomly allocated to two groups: The outcome of the trial was improving the quality of sleep. Other primary outcomes on feasibility and applicability of the intervention were collected through nominal groups. Description of usual care was described through previous studies. Moreover we assessed recruitment process, compliance with the intervention sessions, and patient's retention.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive behavioral therapy for insomnia
N/A

Detailed Description

Objectives

The primary objectives of this pilot-feasibility study were:
  1. To design and adapt a brief CBT-i intervention to be provided by PCPs for the treatment of chronic insomnia in individuals who are 18 to 65 years-old.

  2. To define usual care (UC) for the treatment of chronic insomnia provided by PCPs as a comparative intervention (control group).

  3. To assess the training activities for the CBT-i intervention by determining GPs' and nurses' satisfaction with the content and applicability of the intervention.

  4. To determine the acceptability of the intervention by GPs and nurses.

  5. To assess PCPs and patient recruitment, follow-up, and adherence to the intervention The secondary objective was to assess the quality of sleep in patients after 3 months of the CBT-i.

Methods Design This pilot-feasibility study of a cluster parallel randomized design comparing CBT-I against usual care (UC) was performed from September 2014 to April 2015 at two primary health care centers of Majorca (Spain) with 56,000 registered inhabitants.

Collection of information and follow up Intervention The CBT-i intervention was developed by two family physicians (IT and CV) and two psychologists (ET and MRP-P). First, a review of the literature on the use of CBT-i was performed, with a focus on interventions applied in primary care. After the literature review, the CBT-i created by Morin [24] was adapted to our setting, in which there were fewer sessions and shorter sessions. The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal (when needed). To conduct the intervention, guidelines for GPs and nurses and graphic and written materials for patients (sleep diary, registry of behavior habits, and cognitive problems) were developed.

Usual care The usual treatment for persistent insomnia in a primary care setting was previously described in two cross-sectional studies performed by general practitioners and family nurses of the Primary Care Majorca Department during 2011 and 2015

Study Design

Study Type:
Interventional
Actual Enrollment :
32 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Asessing the Feasibility and Acceptability of a Cluster Randomized Study of Cognitive Behavioral Therapy for Chronic Insomnia in a Primary Care.
Actual Study Start Date :
Sep 1, 2014
Actual Primary Completion Date :
Apr 1, 2015
Actual Study Completion Date :
Nov 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cognitive behavioral therapy (CBT)

5 sessions of Cognitive behavioral therapy for insmonia and an extra session for benzodiazepine withdrawal (if necessary). The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal

Behavioral: Cognitive behavioral therapy for insomnia
is a multicomponent intervention which focuses on cognitive and behavioral factors that contribute to sleep disorders , The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal (when needed). To conduct the intervention, guidelines for GPs and nurses and graphic and written materials for patients (sleep diary, registry of behavior habits, and cognitive problems) were developed

No Intervention: Usual care

Usual care from GPs or nurses

Outcome Measures

Primary Outcome Measures

  1. Acceptability of the training of PCPs [3 months postintervention]

    Satisfaction with training content and its ability to provide sufficient training measured though 2 nominal groups with a previous script

Secondary Outcome Measures

  1. Feasibility of the intervention [3 months postintervention]

    Adequacy of sessions in terms of content, duration and number, fitting in PCPs agenda and patients acceptance.

  2. Feasibility of the study design [3 months postintervention]

    Number of patients eligible identified and included, number of PCP randomized, number of patients followed up,completion of follow up and adherence to intervention sessions.

  3. Intervention Effectiveness: Sleep [pretreatment and 3 months postintervention]

    The Pittsburgh Sleep Quality Index (PSQI) is a 19-items self reported questionnaire that assesses 7 clinical components of sleep quality. Each item is rated on 0 to 3 point scale in which 0 is equal to not in the past month and 3 is equal to 3 or more times a week, with a global score range from 0 to 21. A cut off score of 5 has shown to discriminate between good and bad sleepers.

  4. Intervention Effectiveness:Anxiety [pretreatment and 3 months postintervention]

    The Hospital Anxiety and Depression Scale (HADS) measures anxiety and depression levels in the preceding week. It is 14-item self-report scale with two 7-item anxiety or depression subscales. Each item scores from 0 to 3 point scale giving maximum subscale scores of 21. Patients with scores >10 are considered to have morbidity, between 8 and 10 as borderline cases and <8 absence of relevant

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion criteria:
  • 18 to 65 years-old

  • Diagnoses of chronic insomnia according to the Insomnia Severity Index (ISI equal or higher than 8) and had insomnia longer than 3 months;

  • Did or did not use a hypnotic medication.

Exclusion criteria:
  • Clinical diagnosis of secondary insomnia or another sleep disorder, such as restless legs syndrome, parasomnia, or alterations of the circadian rhythm (e.g., due to shift work)

  • Use of a medication that could produce sleep alterations

  • Severe psychiatric disorder; depression (HADS score ≥ 8) or diagnosis of major depression in the clinical records

  • Suicide attempt

  • Use of an antidepressant or anti-psychotic medication

  • Alcohol or drug abuse during the last year

  • Reception of another CBT-i

  • Sleep apnea

  • Dementia or presence of a cognitive deficit (Mini Mental State Evaluation score lower than 23)

  • Neurodegenerative or oncological disease with poor prognosis

  • Mental or physical incapacities that impeded participation in interviews

  • Acute or chronic pain secondary to a rheumatic disease or another untreated chronic disease

  • Pregnancy

  • Participation in a previous clinical trial in the participating health centers

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Balearic Islands Health Service (Ibsalut)

Investigators

  • Principal Investigator: Isabel Torrens, MD, Santa Ponça health Care Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Isabel Torrens, Researcher, Balearic Islands Health Service (Ibsalut)
ClinicalTrials.gov Identifier:
NCT04565223
Other Study ID Numbers:
  • PI14/019
First Posted:
Sep 25, 2020
Last Update Posted:
Sep 25, 2020
Last Verified:
Sep 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Isabel Torrens, Researcher, Balearic Islands Health Service (Ibsalut)
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 25, 2020